Marion Merrell Dow
Executive Summary
Collaboration with Mitsubishi Kasei covers the North American development and marketing of pharmaceutical products discovered by the Japanese company. Under the agreement announced April 8, the two firms will review Mitsubishi Kasei compounds that are currently in clinical development in Japan, as well as compounds that enter clinical trials in the next seven years. Some of the products to be covered under the agreement are already in Phase II trials in Japan, though none have begun clinical trials in the U.S.